Alexander Spira, MD, PhD, FACP

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    CytomX Therapeutics
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    AstraZeneca/MedImmune
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Merck
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Takeda
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Amgen
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Janssen Oncology
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Novartis
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Bristol-Myers Squibb
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Bayer
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    incyte
    Date added:
    08/16/2023
    Date updated:
    08/16/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond